Drug Recalls

Voluntary Recall: Two Lots of NP Thyroid® Tablets, Due to Sub Potency

Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Two Lots of NP Thyroid®, Thyroid Tablets, USP Due to Sub Potency

Date of Release: Sept. 18, 2020 

ATLANTA /PRNewswire/ — Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level. The products are being recalled because testing has found these lots to be sub potent. The product may have as low as 87% of the labeled amount of levothyroxine (T4). More information can be found at www.npthyroid.com/product-updates.

Risk Statement: Patients being treated for hypothyroidism (underactive thyroid), who receive sub potent NP Thyroid®, may experience signs and symptoms of hypothyroidism (underactive thyroid) which may include, fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight. There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development. In elderly patients and patients with underlying cardiac disease toxic cardiac manifestations of hyperthyroidism may occur, such as cardiac pain, palpitations or cardiac arrhythmia. To date, Acella has received four reports of adverse events for these lot numbers possibly related to this recall.

NP Thyroid®, Thyroid Tablets, USP is composed of levothyroxine and liothyronine, and used to treat hypothyroidism (underactive thyroid). The products subject to recall are packed in 100-count bottles. See product images.

To best identify the product, the NDC’s, Product Description, Lot Numbers and Expiration Dates are listed. These lots were distributed nationwide in the USA to Acella’s direct accounts, including wholesalers, pharmacies, and healthcare offices. Additionally, consumers may be able to determine that their product is not impacted by the recall if the “use by,” “discard after,” or “expiration date” on their prescription bottle is on or after December 2020.

Product NDCLot #Exp. Date
NP Thyroid® 15, Thyroid Tablets, USP,¼ grain (15 mg)42192-327-01M327E19-1October 2020
NP Thyroid® 120, Thyroid Tablets, USP,2 grain (120 mg)42192-328-01M328F19-3November 2020

See Product Labels:

Acella is proactively notifying its wholesalers by email and phone to discontinue distribution of the two above referenced lots being recalled and is arranging for return of all recalled products. Patients who are currently taking NP Thyroid® from the lots being recalled should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.

Consumers with questions about the recall can email Acella Pharmaceuticals at recall@acellapharma.com or contact our representatives at 1-888-280-2044, Monday through Friday from 8:00 am to 5:00 pm ET. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse events or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

SOURCE Acella Pharmaceuticals

Medika Life

Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Recent Posts

Executive action may actually drive up medicines prices

*This story will be updated as more details become available* President Trump’s executive order could…

1 day ago

Trump’s Drug Price Gambit: Cheaper for America, But Who Pays the Price?

Donald Trump is back at it, making big waves in the world of pharmaceuticals. On…

1 day ago

Cancer Isn’t Random: What 42% of Diagnoses Have in Common — and How You Can Lower Your Risk.

“The fault, dear Brutus, is not in our stars, but in ourselves…”— William Shakespeare, Julius Caesar.…

2 weeks ago

When Is Exercise Not Exercise, and Is That Good Enough?

Going for walks, dancing, and doing housework —although not technically exercises —any kind of movement counts toward your…

2 weeks ago

How Real-World Evidence Proves the Power of Patient Engagement

Data isn’t just an asset—it’s a trust marker. In life sciences, our credibility hinges on…

3 weeks ago

This 5-Minute Habit Could Help Prevent a Dangerous Heart Condition.

At 7:28 a.m., the sidewalk was still damp from last night’s Seattle area rain. I…

3 weeks ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More